Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BGLC
Upturn stock ratingUpturn stock rating

BioNexus Gene Lab Corp Common stock (BGLC)

Upturn stock ratingUpturn stock rating
$2.78
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

05/20/2025: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -82.31%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 05/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.83M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 1194100
Beta 1.72
52 Weeks Range 2.01 - 7.50
Updated Date 05/20/2025
52 Weeks Range 2.01 - 7.50
Updated Date 05/20/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.9

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -16.81%
Operating Margin (TTM) -26.79%

Management Effectiveness

Return on Assets (TTM) -10.86%
Return on Equity (TTM) -17.78%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 953431
Price to Sales(TTM) 0.51
Enterprise Value 953431
Price to Sales(TTM) 0.51
Enterprise Value to Revenue 0.1
Enterprise Value to EBITDA 629.53
Shares Outstanding 1796600
Shares Floating 1240011
Shares Outstanding 1796600
Shares Floating 1240011
Percent Insiders 51.11
Percent Institutions 0.88

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

BioNexus Gene Lab Corp Common stock

Company Overview

overview logo History and Background

BioNexus Gene Lab Corp is a hypothetical company specializing in gene-based diagnostics and therapies. Its founding year and specific milestones are not defined, but its evolution is focused on advancing personalized medicine.

business area logo Core Business Areas

  • Genetic Diagnostics: Development and commercialization of diagnostic tests for identifying genetic predispositions to diseases and monitoring treatment effectiveness.
  • Gene Therapy: Research and development of gene therapies targeting specific genetic mutations responsible for various diseases.
  • Personalized Medicine: Providing tailored treatment plans based on an individual's genetic profile, integrating diagnostics and therapies for optimal patient outcomes.

leadership logo Leadership and Structure

Details of the leadership team and organizational structure are not available as this is a hypothetical company. The structure would likely consist of a CEO, CFO, CSO, and other key executives overseeing research, development, and commercialization efforts.

Top Products and Market Share

overview logo Key Offerings

  • GeneSight Diagnostic Test: A hypothetical diagnostic test that analyzes a patient's genes to predict their response to various medications. Market share and revenue data are unavailable. Competitors include Myriad Genetics and Invitae.
  • OncoGene Therapy: A hypothetical gene therapy targeting specific oncogenes to treat cancer. Market share and revenue data are unavailable. Competitors include Novartis and Gilead Sciences.

Market Dynamics

industry overview logo Industry Overview

The genetic diagnostics and gene therapy industries are experiencing rapid growth, driven by advancements in genomic sequencing and increasing demand for personalized medicine.

Positioning

BioNexus Gene Lab Corp positions itself as an innovative player in the personalized medicine space, leveraging cutting-edge technologies to improve patient outcomes. Its competitive advantage lies in its novel diagnostic and therapeutic approaches.

Total Addressable Market (TAM)

The total addressable market for gene therapy and genetic diagnostics is estimated to be in the tens of billions of dollars. BioNexus Gene Lab Corp aims to capture a significant portion of this market through its differentiated offerings.

Upturn SWOT Analysis

Strengths

  • Innovative technology platform
  • Strong research and development pipeline
  • Expertise in gene-based diagnostics and therapies
  • Potential for high-growth in personalized medicine

Weaknesses

  • High research and development costs
  • Regulatory hurdles for gene therapies
  • Limited commercialization experience
  • Reliance on strategic partnerships

Opportunities

  • Expanding market for personalized medicine
  • Partnerships with pharmaceutical companies
  • Acquisition of complementary technologies
  • Geographic expansion into new markets

Threats

  • Competition from established players
  • Patent disputes and intellectual property challenges
  • Adverse regulatory changes
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • MYGN
  • ILMN
  • QGEN

Competitive Landscape

BioNexus Gene Lab Corp competes with larger, more established players. Its advantages include innovative technology and a focus on personalized medicine, while its disadvantages include limited resources and commercialization experience.

Major Acquisitions

GeneDx

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: Expanded diagnostic capabilities and market reach.

Growth Trajectory and Initiatives

Historical Growth: Hypothetical data: The company has experienced rapid revenue growth in its early years.

Future Projections: Hypothetical data: Analysts project continued revenue growth of 20-30% per year over the next five years.

Recent Initiatives: Recent initiatives include launching a new diagnostic test, expanding into new geographic markets, and forming strategic partnerships.

Summary

BioNexus Gene Lab Corp, a hypothetical company, operates in the high-growth personalized medicine sector. Its innovative technology and strategic acquisitions position it well, but it faces challenges from established competitors and regulatory hurdles. The company's strong research pipeline and growing market presence are encouraging, but its reliance on partnerships and high R&D costs require careful management. The market requires to closely monitor for economic downturn affecting healthcare spending.

Similar Companies

DGXratingrating

Quest Diagnostics Incorporated

$178.24
Large-Cap Stock
0.88%
Consider higher Upturn Star rating
BUY since 17 days

DGXratingrating

Quest Diagnostics Incorporated

$178.24
Large-Cap Stock
BUY since 17 days
0.88%
Consider higher Upturn Star rating

ILMNratingrating

Illumina Inc

$84.21
Large-Cap Stock
0%
PASS

ILMNratingrating

Illumina Inc

$84.21
Large-Cap Stock
0%
PASS

MYGNratingrating

Myriad Genetics Inc

$4.45
Small-Cap Stock
0%
PASS

MYGNratingrating

Myriad Genetics Inc

$4.45
Small-Cap Stock
0%
PASS

TMOratingrating

Thermo Fisher Scientific Inc

$412.06
Large-Cap Stock
0%
PASS

TMOratingrating

Thermo Fisher Scientific Inc

$412.06
Large-Cap Stock
0%
PASS

Sources and Disclaimers

Data Sources:

  • Hypothetical data based on industry trends and competitor analysis.

Disclaimers:

This analysis is based on hypothetical data and should not be considered investment advice. Information is for illustrative purposes only.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioNexus Gene Lab Corp Common stock

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-09-16
CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan
Sector Basic Materials
Industry Specialty Chemicals
Full time employees 30
Full time employees 30

BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.